Log in

NYSE:MCKMcKesson Stock Price, Forecast & News

$158.67
+2.21 (+1.41 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$155.11
Now: $158.67
$159.07
50-Day Range
$129.42
MA: $139.20
$156.86
52-Week Range
$112.60
Now: $158.67
$172.18
Volume1.60 million shs
Average Volume1.51 million shs
Market Capitalization$28.07 billion
P/E Ratio30.93
Dividend Yield1.05%
Beta0.82
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. It also provides specialty pharmaceutical solutions for pharmaceutical manufacturers; and medical-surgical supply distribution, logistics, and other services to healthcare providers. In addition, the company operates retail pharmacy chains in Europe and Canada, as well as supports independent pharmacy networks within North America and Europe; and supplies integrated pharmacy management systems, automated dispensing systems, and related services to retail, outpatient, central fill, specialty, and mail order pharmacies. Further, it provides software and analytics, network solutions, and technology-enabled services. The company serves retail national accounts, including national and regional chains, food and drug combinations, mail order pharmacies, and mass merchandisers; independent retail pharmacies; and institutional healthcare providers, such as hospitals, health systems, integrated delivery networks, and long-term care providers, as well as pharmaceutical manufacturers. McKesson Corporation was founded in 1833 and is headquartered in San Francisco, California.
Read More
McKesson logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 3.1Dividend Strength: 4.2Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.25 out of 5 stars


Industry, Sector and Symbol

Industry Drugs, proprietaries, & sundries
Sub-IndustryHealth Care Distributors
SectorMedical
CUSIP58155Q10
Phone972-446-4800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$231.05 billion
Cash Flow$21.59 per share
Book Value$30.01 per share

Profitability

Net Income$900 million

Miscellaneous

Employees80,000
Market Cap$28.07 billion
Next Earnings Date7/29/2020 (Estimated)
OptionableOptionable

Receive MCK News and Ratings via Email

Sign-up to receive the latest news and ratings for MCK and its competitors with MarketBeat's FREE daily newsletter.

McKesson (NYSE:MCK) Frequently Asked Questions

How has McKesson's stock been impacted by COVID-19 (Coronavirus)?

McKesson's stock was trading at $135.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MCK shares have increased by 17.4% and is now trading at $158.67. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of McKesson?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for McKesson.

When is McKesson's next earnings date?

McKesson is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for McKesson.

How were McKesson's earnings last quarter?

McKesson Co. (NYSE:MCK) announced its quarterly earnings data on Wednesday, May, 20th. The company reported $4.27 EPS for the quarter, beating analysts' consensus estimates of $4.10 by $0.17. The business earned $58.54 billion during the quarter, compared to the consensus estimate of $55.60 billion. McKesson had a net margin of 0.39% and a return on equity of 41.07%. The firm's revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.69 EPS. View McKesson's earnings history.

How often does McKesson pay dividends? What is the dividend yield for McKesson?

McKesson announced a quarterly dividend on Wednesday, April 29th. Investors of record on Monday, June 1st will be paid a dividend of $0.41 per share on Wednesday, July 1st. This represents a $1.64 annualized dividend and a dividend yield of 1.03%. The ex-dividend date of this dividend is Friday, May 29th. View McKesson's dividend history.

What guidance has McKesson issued on next quarter's earnings?

McKesson issued an update on its FY21 earnings guidance on Wednesday, May, 20th. The company provided earnings per share guidance of $13.95-14.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $15.48. The company issued revenue guidance of +2-4% to $218.6-222.9 billion, compared to the consensus revenue estimate of $234.49 billion.

What price target have analysts set for MCK?

15 analysts have issued 12 month target prices for McKesson's shares. Their forecasts range from $146.00 to $197.00. On average, they anticipate McKesson's stock price to reach $170.00 in the next twelve months. This suggests a possible upside of 7.1% from the stock's current price. View analysts' price targets for McKesson.

Has McKesson been receiving favorable news coverage?

News headlines about MCK stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. McKesson earned a media sentiment score of -3.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutMcKesson.

Are investors shorting McKesson?

McKesson saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,800,000 shares, an increase of 20.6% from the April 30th total of 3,150,000 shares. Based on an average trading volume of 5,200,000 shares, the days-to-cover ratio is presently 0.7 days. Approximately 2.2% of the company's stock are short sold. View McKesson's Current Options Chain.

Who are some of McKesson's key competitors?

What other stocks do shareholders of McKesson own?

Based on aggregate information from My MarketBeat watchlists, some companies that other McKesson investors own include Walt Disney (DIS), Gilead Sciences (GILD), CVS Health (CVS), salesforce.com (CRM), UnitedHealth Group (UNH), Johnson & Johnson (JNJ), Allergan (AGN), Bank of America (BAC), AbbVie (ABBV) and Chevron (CVX).

Who are McKesson's key executives?

McKesson's management team includes the following people:
  • Mr. John H. Hammergren, Chairman & CEO (Age 60)
  • Britt J. Vitalone, CFO & Exec. VP (Age 50)
  • Ms. Lori A. Schechter, Chief Compliance Officer, Exec. VP & Gen. Counsel (Age 57)
  • Mr. Jorge L. Figueredo, Exec. VP & Chief HR Officer (Age 58)
  • Mr. Bansi Nagji, Exec. VP and Chief Strategy & Bus. Devel. Officer (Age 54)

What is McKesson's stock symbol?

McKesson trades on the New York Stock Exchange (NYSE) under the ticker symbol "MCK."

Who are McKesson's major shareholders?

McKesson's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.10%), State Street Corp (4.32%), Massachusetts Financial Services Co. MA (3.16%), Invesco Ltd. (2.78%), Pzena Investment Management LLC (1.95%) and Geode Capital Management LLC (1.57%). Company insiders that own McKesson stock include Brian S Tyler, Brian Scott Tyler, Britt J Vitalone, Erin M Lampert, Lori A Schechter, M Christine Jacobs, N Anthony Coles and Sundeep G Reddy. View institutional ownership trends for McKesson.

Which institutional investors are selling McKesson stock?

MCK stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Wellington Management Group LLP, APG Asset Management N.V., BlackRock Inc., APG Asset Management N.V., APG Asset Management N.V., AJO LP, and State Street Corp. Company insiders that have sold McKesson company stock in the last year include Brian S Tyler, Brian Scott Tyler, Britt J Vitalone, Lori A Schechter, M Christine Jacobs, and Sundeep G Reddy. View insider buying and selling activity for McKesson.

Which institutional investors are buying McKesson stock?

MCK stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., The Manufacturers Life Insurance Company , BNP Paribas Arbitrage SA, Canada Pension Plan Investment Board, Balyasny Asset Management LLC, Parametric Portfolio Associates LLC, Strs Ohio, and Massachusetts Financial Services Co. MA. View insider buying and selling activity for McKesson.

How do I buy shares of McKesson?

Shares of MCK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is McKesson's stock price today?

One share of MCK stock can currently be purchased for approximately $158.67.

How big of a company is McKesson?

McKesson has a market capitalization of $28.07 billion and generates $231.05 billion in revenue each year. The company earns $900 million in net income (profit) each year or $14.95 on an earnings per share basis. McKesson employs 80,000 workers across the globe.

What is McKesson's official website?

The official website for McKesson is www.mckesson.com.

How can I contact McKesson?

McKesson's mailing address is 6555 STATE HWY 161, IRVING TX, 75039. The company can be reached via phone at 972-446-4800 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.